merck set bar clear
pt
tuesday aduro announc result attent remain focus first-in-
human result slate present share
face sharp pressur rel xbi wake mediocr clinic
data merck sting program esmo includ lack monotherapi activ
given one-year head start merck believ aduro partner novarti
could present matur set clinic result potenti reignit investor
enthusiasm sting pathway reiter outperform rate lower
pt previous reflect slower expect develop timelin
pladd program importantli compani
cash posit could sustain oper provid oper freedom
continu develop program
expect see monotherapi dose-escal result novarti phase
trial poster present abstract
novemb follow earli result combin portion trial
inhibitor aduro investor event day convers
manag suggest combin result limit scope
earlier month merck present earli data sting agonist
mix solid tumor monotherapi object
respons treatment-evalu patient keytruda combin cohort
pr observ evalu patient view intratumor
approach oncolyt virus yield impress result
believ novarti may enrol tougher-to-treat patient rel
merck studi exampl merck trial allow nave patient receiv
combin therapi wherea novarti combin arm mandat prior
exposur view merck set low bar aduro/novarti clear
would view unambigu monotherapi activ favor
also evalu combin ipilumumab
acknowledg extra time phase may requir identifi optim
treatment paramet similarli phase timelin aduro pladd
program extend beyond initi project
push back commerci launch timelin three program year
addit present slate expect learn
first detail new preclin asset includ new program target
innat immun checkpoint aduro post net loss
line expect loss aduro end
cash equival could sustain oper
immunotherapi compani focus
commerci novel therapi
analyst certif import disclosur see disclosur
approv peak sale us eu
approv pladd peak sale us eu
approv anti-april antibodi peak sale us
eu
earlier anticip trial result regulatori approv
success develop sting modul addit
potenti mileston payment merck develop
assign outperform rate month
price target base convict compani
success develop commerci sever clinical-
stage program current ascrib valu three program
pladd microsatellite-st colorect cancer
melanoma anti-april antibodi multipl myeloma
believ could achiev regulatori approv late
po pladd could approv po
anti-april could approv po
potenti report dose-escal result phase
monotherapi trial
potenti present interim phase result pladd
potenti present interim phase result
combin mix solid tumor
potenti present interim phase result anti-april
clinical/regulatori failur pladd anti-april
termin co-develop co-commerci
partnership novarti
termin merck partnership potenti creat neg
month price target per share deriv risk-adjust sum-of-the-part npv valuat aduro
per share contribut probabl success pladd per share contribut po anti-april program
per share contribut po includ project net cash contribut per share round
arriv price target
risk includ clinic regulatori competit market price pressur partnership risk
note stock trade may consid specul appropri risk-toler investor
multipl tumor
potenti report dose-escal result phase monotherapi trial
potenti present earli data phase trial combin inhibitor
pladd mss-crc
potenti present updat immun respons data phase trial pladd mss-crc
anti-april antibodi multipl myeloma
potenti present updat preclin data
potenti interim result phase studi multipl myeloma
compani present oppenheim co
updat valuat chang describ valu aduro
use probability-weight sum-of-the-part npv methodolog summar
exhibit model includ contribut three differ program
believ embodi compani three platform technolog
treatment solid tumor metastat melanoma probabl success
regulatori approv commerci launch previous pladd
treatment microsatellit stabl mss colorect cancer po
regulatori approv commerci launch previous bion-
anti-april antibodi treatment relapsed/refractori multipl myeloma
po regulatori approv commerci launch previous
expect compani end cash posit last includ
project cash posit per share arriv price target
round
figur thousand except per share licens expens good sold research develop gener administr intang oper loss incom expens gain loss remeasur fair valu warrant interest incom expens incom expens total incom expens loss incom incom tax benefit incom per share share outstand comark breidenbach outperform
figur thousand except per share asset cash market tax expens current current market equip asset cash assetsoth assetstot stockhold equitycurr liabil account clinic trial manufactur expens current tax long term equiti common paid-in comprehens incom stockhold liabil stockhold comark breidenbach aduro
stock price compani mention report close
